Cystic Fibrosis Devices Market
Cystic Fibrosis Devices Market Analysis by Oral and Parenteral ROA for Hospitals, Retail Pharmacies & Drug Stores, and Online Pharmacies from 2023 to 2033
Analysis of Cystic Fibrosis Devices Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Cystic Fibrosis Devices Market Outlook (2023 to 2033)
The global cystic fibrosis devices market is currently valued at US$ 825.09 million and is expected to increase at a massive CAGR of 10% from 2023 to 2033 and is projected to reach US$ 2.14 billion by 2033.
A hereditary condition brought on by gene mutations is known as cystic fibrosis (CF). The lungs, digestive system, and other body organs are severely damaged by the genetic illness 'cystic fibrosis'.
The cells that make sweat, digestive fluids, and mucus are impacted by cystic fibrosis. These secreted fluids are often slick and thin. However, a genetic defect in cystic fibrosis patients results in thick, sticky secretions. In the lungs and pancreas, in particular, the secretions clog up tubes, ducts, and passageways rather than lubricating them.
Individuals with CF disease who have an increase in upper and lower respiratory tract infections are driving up demand for cystic fibrosis treatment devices. The prevalence of blood in sputum, chronic cough, and collapsed lungs are further boosting sales of cystic fibrosis inhalation devices.
Furthermore, due to difficulties absorbing proteins, lipids, and vitamins, individuals with CF condition also struggle with gastrointestinal system diseases, which are also influencing the growth of the cystic fibrosis devices market. As a result, it is anticipated that the availability of various medications for the treatment of respiratory and gastrointestinal infections as well as the availability of over-the-counter medications for the treatment of the reproductive system will have a positive effect on the growth of the market for cystic fibrosis therapeutics during the forecast period.
According to this study by Fact.MR, a market research and competitive intelligence provider, the cystic fibrosis devices market is classified into medications and devices. Based on medication, the market is further segmented into cystic fibrosis transmembrane conductance regulator (CFTR) modulators, mucolytics, bronchodilators, and pancreatic enzyme supplements.
Several drugs, gadgets, and surgeries are used as cystic fibrosis treatments to slow the disease's progression. As a chloride channel in the body, the transmembrane conductance regulator (CFTR) protein aids in controlling the movement of sodium and chlorine into and out of the cell membranes of the lungs and other body organs. CFTR modulators improve cellular body function and patients' quality of life while reducing lung-related ailments and respiratory problems.
A significant market share currently belongs to CFTR drugs, which are expected to rise significantly in the coming years. Additionally, the cystic fibrosis industry growth will be fueled by additional cutting-edge treatments including triple combination medications with CFTR modulators.
Other types of medications, including antibiotics, anti-inflammatory medicines, pancreatic enzyme supplements, and mucolytics, are also used to address gastrointestinal problems or increase airway clearance in patients suffering from cystic fibrosis genetic disease.
| Report Attributes | Details |
|---|---|
| Cystic Fibrosis Devices Market Size (2023E) | US$ 825.09 Million |
| Forecasted Market Value (2033F) | US$ 2.14 Billion |
| Global Market Growth Rate (2023 to 2033) | 10% CAGR |
| China Market Growth Rate (2023 to 2033) | 14.5% CAGR |
| Japan Market Growth Rate (2023 to 2033) | 5% CAGR |
| Germany Market Growth Rate (2023 to 2033) | 6% CAGR |
| Canada Market Growth Rate (2023 to 2033) | 8.5% CAGR |
| Key Companies Profiled | AbbVie; Allergan Plc; AstraZeneca; Bayer AG; Chiesi Farmaceutici S.p.A.; F. Hoffmann-La Roche AG; Genentech, Inc.; Gilead Sciences; Mylan N.V.; Novartis AG; Pfizer Inc.; Pharmaxis Ltd.; PTC Therapeutics; Vertex Pharmaceuticals Incorporated |
Don't Need a Global Report?
save 40%! on Country & Region specific reports
What is the Global Demand Outlook for Cystic Fibrosis Devices?
“COVID-19 Had Positive Impact on Sales of Cystic Fibrosis Devices”
Since cystic fibrosis patients are at a greater risk of contracting the coronavirus, the sudden global spread of the COVID-19 outbreak is boosting the cystic fibrosis therapeutics market growth. The rising prevalence of several CF-associated diseases such as lung infections, pancreatic inflammation, diabetes, and others are expected to significantly boost the sales of cystic fibrosis devices.
- For instance, data on COVID-19-infected CF patients are being collected and analysed by the European Cystic Fibrosis Society (ECFS). Information is being gathered and reported by the ECFS Patient Registry in collaboration with national cystic fibrosis registries to determine the variables that predict the severity of COVID-19.
“Rising Prevalence of Cystic Fibrosis Disease & Related Disorders”
The primary factor anticipated to boost the growth of airway clearance devices for the cystic fibrosis market is the rising prevalence of cystic fibrosis, asthma, and chronic obstructive pulmonary disease (COPD) around the globe. The prevalence of lung-related ailments brought on by cigarette usage and increasing worries about respiratory illnesses including emphysema and asthma are the main factors fuelling sales of cystic fibrosis airway clearance devices.
Additionally, several growth opportunities in the cystic fibrosis (CF) therapeutics market are anticipated to develop throughout the forecast period due to elements including rising spending power on healthcare, increasing use of automation in the healthcare sector, and quick uptake of cutting-edge medication devices.
Several technological advancements are boosting the demand for improved home respiratory therapy devices. Due to their quick and efficient results, the majority of healthcare professionals and experts in lung disorders now favour medicine and device combinations, such as inhalers and nebulizers.
Favourable insurance coverage provided by the public and private sectors, particularly in developed nations, for the use of airway clearance devices for various respiratory disorders is anticipated to have a positive impact on the cystic fibrosis therapeutics market growth.
Companies such as Hill-Rom and Electromed, Inc. provide efficient medical care along with simple reimbursement. Over the projection period, it is anticipated that increasing awareness of the need to establish a unified platform for chronic obstructive pulmonary disease patients will propel global cystic fibrosis devices market growth.
- For instance, November is observed globally as National COPD Month. To increase awareness, the COPD Foundation works with multiple respiratory healthcare groups to organize various in-person and online events for people with COPD.
- For example, Vertex Pharmaceuticals Incorporated recently reported encouraging findings from their phase III clinical trial on inhaled mannitol used to treat mucociliary clearance.
In addition to this, the demand for cystic fibrosis devices is anticipated to grow due to the use of technologically sophisticated devices for a range of serious cases, such as mucus thinners, airway clearance procedures, and others. Thus, all such aspects are boosting the demand for cystic fibrosis medical devices.
“Rapid Developments in Cystic Fibrosis Treatment Procedures”
The size of the CF patient population is rising rapidly across the world. Pharmacotherapy for cystic fibrosis has made several improvements in the way this ailment is treated, which is boosting demand for cystic fibrosis devices.
In addition, industry trends in illness treatment are driving sales growth since more pipeline candidates from big businesses are geared toward therapeutic procedures. Manufacturers are being influenced by this to develop cutting-edge drugs that target anomalies in the CFTR protein.
The introduction of Ivacaftor/Lumacaftor, a potentiator that enhances the lives of those with CF disease, is also contributing to the growth of the market. Furthermore, prominent businesses' increased R&D efforts and technological advancements are fuelling the sales of cystic fibrosis equipment by offering advanced products.
For instance :
- The National Research Council introduced a smart patch for the early identification of cystic fibrosis. This patch is wirelessly powered in the digital realm.
Which Factors May Hamper Sales of Cystic Fibrosis Medication Devices?
“Adverse Effects of Some Medications and High Cost of Treatments”
Some aspects are expected to negatively influence sales growth during the forecast period. Utilization of some cystic fibrosis medication products can result in severe side effects such as upper respiratory tract infections, liver issues, chest pain, and high blood pressure which further limit the market growth.
Furthermore, the exorbitant expense of care for CF patients requiring a liver transplant, a lung transplant, and other transplants is impeding demand for cystic fibrosis gene therapy solutions.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Country-wise Analysis
How is Demand for Cystic Fibrosis Devices Evolving in the United States?
“Rapidly Increasing Cases of Lung Disorders”
The United States is currently holding a leading position in the North American cystic fibrosis market. The rising cases of chronic obstructive pulmonary disease and asthma are supporting the sales of cystic fibrosis devices in the nation.
Development of the United States cystic fibrosis devices market is also being aided by technologically advanced healthcare facilities and growing public awareness of early therapies for lung-related disorders. Additionally, the demand for cystic fibrosis drug therapies is being aided by the introduction of innovative treatment modalities such as targeted drug therapy and stereotactic drug delivery.
- The American Lung Association ranks COPD as the third leading cause of death in the nation.
Why are Germany & the United Kingdom Rapidly Progressing in the Field of Cystic Fibrosis Treatment?
“Presence of Advanced Healthcare Facilities and Rapid Technological Advancements”
Rising demand for cystic fibrosis devices in Germany & the United Kingdom can be attributed to well-established healthcare infrastructure and advantageous medical insurance policies. The risk of cystic fibrosis is expected to increase in European countries due to the rising incidence of genetic abnormalities.
The market in Germany is expected to increase at a CAGR of 6% from 2023 to 2033. Furthermore, government attempts to raise awareness about the importance of routine lung examinations are driving demand for cystic fibrosis (CF) therapeutics.
Chronic lung illnesses and asthma are the most prevalent condition among children in the European region. The usage of artificial intelligence (AI) and the internet of things (IoT), among other technological developments, are boosting sales growth in the field of cystic fibrosis diagnosis.
What is Supporting the Sales of Cystic Fibrosis Devices in China?
“Rapidly Growing Rate of Senior Population”
The market for cystic fibrosis devices in the Asia Pacific region is projected to increase due to the rapidly rising rate of the ageing population who are more susceptible to lung-related ailments in developing nations such as Japan, South Korea, and China.
Demand for cystic fibrosis medication devices in China is predicted to progress at a CAGR of 14.5% during the next 10 years. The factors driving sales growth include the high adoption of cutting-edge technologies and the rapidly growing healthcare industry.
- With strong clinical development capabilities and a significant commercial presence in China, Innovent is a top biopharmaceutical business.
Category-wise Analysis
Which Route of Administration is Highly Preferred for Cystic Fibrosis Treatment?
“Easy & Comfortable Consumption Aspects Driving Sales of Oral Drugs”
Based on route of administration, the cystic fibrosis cure procedure is segmented into oral and parenteral. Currently, oral drug holds a dominating share in the cystic fibrosis devices market. This growth can be related to elements such as the increasing use of oral medications worldwide and the introduction of novel drug formulations that can be readily swallowed without the risk of intrusive treatments to obtain effective therapy.
In addition, the parenteral drug demand is predicted to rise healthily over the forecast period due to rising interest in parenteral medication, which includes injections and inhalation. As a result, medical professionals often prescribe inhaled medications to patients who suffer from CF and high-risk respiratory illnesses.
Furthermore, key companies in the cystic fibrosis devices market are concentrating on the mass production of advanced formulation injections due to an increase in the usage of injections for the treatment of CF.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Competitive Landscape
Some of the key players in the cystic fibrosis devices market are AbbVie, Allergan Plc, AstraZeneca, Bayer AG, Chiesi Farmaceutici S.p.A., F. Hoffmann-La Roche AG, Genentech, Inc., Novartis AG, Pfizer Inc., and Vertex Pharmaceuticals Incorporated.
- Vertex Pharmaceuticals Incorporated holds a dominating market position due to its wide range of products and significant global presence in the treatment of cystic fibrosis. Vertex Pharmaceuticals is a biotechnology company that focuses on scientific breakthroughs to create effective treatment products for critical diseases. For cystic fibrosis treatment, the firm has numerous authorized medications.
Several leading market participants are adopting local supply marketing strategies such as new developments in product standards based on regional or local needs, changing pricing trends, and improving supply chain management.
- In October 2020, Roche announced a partnership with AbbVie and the procurement of the TMEM16A potentiators portfolio, both of which would be used to treat cystic fibrosis patients regardless of their CFTR genotype as well as those who suffer from other respiratory ailments. The partnership is influencing the company's ability to expand its product line.
Key Segments of Cystic Fibrosis Devices Industry Research
-
By Treatment Method:
- Medications
- Devices
-
By Route of Administration:
- Oral
- Parenteral
-
By Distribution Channel:
- Hospitals
- Retail Pharmacies & Drug Stores
- Online Pharmacies
-
By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia & Oceania
- MEA
Table of Content
- 1. Global Market - Executive Summary
- 2. Global Market Overview
- 3. Market Risks and Trends Assessment
- 4. Market Background and Foundation Data Points
- 5. Global Market Demand (US$ Mn) Analysis 2018 to 2022 and Forecast, 2023 to 2033
- 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment Method
- 6.1. Medications
- 6.2. Devices
- 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, by Route of Administration
- 7.1. Oral
- 7.2. Parenteral
- 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, by Distribution Channel
- 8.1. Hospitals
- 8.2. Retail Pharmacies & Drug Stores
- 8.3. Online Pharmacies
- 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, by Region
- 9.1. North America
- 9.2. Latin America
- 9.3. Europe
- 9.4. East Asia
- 9.5. South Asia & Oceania
- 9.6. Middle East and Africa (MEA)
- 10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033
- 11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033
- 12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033
- 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033
- 14. South Asia & Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033
- 15. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033
- 16. Market Structure Analysis
- 17. Competition Analysis
- 17.1. AbbVie
- 17.2. Allergan Plc
- 17.3. AstraZeneca
- 17.4. Bayer AG
- 17.5. Chiesi Farmaceutici S.p.A.
- 17.6. F. Hoffmann-La Roche AG
- 17.7. Genentech, Inc.
- 17.8. Gilead Sciences
- 17.9. Mylan N.V.
- 17.10. Novartis AG
- 17.11. Pfizer Inc.
- 17.12. Pharmaxis Ltd.
- 17.13. PTC Therapeutics
- 17.14. Vertex Pharmaceuticals Incorporated
- 18. Assumptions and Acronyms Used
- 19. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market Value (US$ Mn) Analysis, by Treatment Method, 2018 to 2022
Table 02: Global Market Value (US$ Mn) Analysis, by Treatment Method, 2023 to 2033
Table 03: Global Market Value (US$ Mn) Opportunity Analysis, by Treatment Method, 2023 to 2033
Table 04: Global Market Value (US$ Mn) Analysis, by Route of Administration, 2018 to 2022
Table 05: Global Market Value (US$ Mn) Analysis, by Route of Administration, 2023 to 2033
Table 06: Global Market Value (US$ Mn) Opportunity Analysis, by Route of Administration, 2023 to 2033
Table 07: Global Market Value (US$ Mn) Analysis, by Distribution Channel, 2018 to 2022
Table 08: Global Market Value (US$ Mn) Analysis, by Distribution Channel, 2023 to 2033
Table 09: Global Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2023 to 2033
Table 10: Global Market Value (US$ Mn) Analysis, by Region, 2018 to 2022
Table 11: Global Market Value (US$ Mn) Analysis, by Region, 2023 to 2033
Table 12: Global Market Value (US$ Mn) Opportunity Analysis, by Region, 2023 to 2033
Table 13: North America Market Value (US$ Mn) Analysis, by Country, 2018 to 2022
Table 14: North America Market Value (US$ Mn) Analysis, by Country, 2023 to 2033
Table 15: North America Market Value (US$ Mn) Opportunity Analysis, by Country, 2023 to 2033
Table 16: North America Market Value (US$ Mn) Analysis, by Treatment Method, 2018 to 2022
Table 17: North America Market Value (US$ Mn) Analysis, by Treatment Method, 2023 to 2033
Table 18: North America Market Value (US$ Mn) Opportunity Analysis, by Treatment Method, 2023 to 2033
Table 19: North America Market Value (US$ Mn) Analysis, by Route of Administration, 2018 to 2022
Table 20: North America Market Value (US$ Mn) Analysis, by Route of Administration, 2023 to 2033
Table 21: North America Market Value (US$ Mn) Opportunity Analysis, by Route of Administration, 2023 to 2033
Table 22: North America Market Value (US$ Mn) Analysis, by Distribution Channel, 2018 to 2022
Table 23: North America Market Value (US$ Mn) Analysis, by Distribution Channel, 2023 to 2033
Table 24: North America Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2023 to 2033
Table 25: Latin America Market Value (US$ Mn) Analysis, by Country, 2018 to 2022
Table 26: Latin America Market Value (US$ Mn) Analysis, by Country, 2023 to 2033
Table 27: Latin America Market Value (US$ Mn) Opportunity Analysis, by Country, 2023 to 2033
Table 28: Latin America Market Value (US$ Mn) Analysis, by Treatment Method, 2018 to 2022
Table 29: Latin America Market Value (US$ Mn) Analysis, by Treatment Method, 2023 to 2033
Table 30: Latin America Market Value (US$ Mn) Opportunity Analysis, by Treatment Method, 2023 to 2033
Table 31: Latin America Market Value (US$ Mn) Analysis, by Route of Administration, 2018 to 2022
Table 32: Latin America Market Value (US$ Mn) Analysis, by Route of Administration, 2023 to 2033
Table 33: Latin America Market Value (US$ Mn) Opportunity Analysis, by Route of Administration, 2023 to 2033
Table 34: Latin America Market Value (US$ Mn) Analysis, by Distribution Channel, 2018 to 2022
Table 35: Latin America Market Value (US$ Mn) Analysis, by Distribution Channel, 2023 to 2033
Table 36: Latin America Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2023 to 2033
Table 37: Europe Market Value (US$ Mn) Analysis, by Country, 2018 to 2022
Table 38: Europe Market Value (US$ Mn) Analysis, by Country, 2023 to 2033
Table 39: Europe Market Value (US$ Mn) Opportunity Analysis, by Country, 2023 to 2033
Table 40: Europe Market Value (US$ Mn) Analysis, by Treatment Method, 2018 to 2022
Table 41: Europe Market Value (US$ Mn) Analysis, by Treatment Method, 2023 to 2033
Table 42: Europe Market Value (US$ Mn) Opportunity Analysis, by Treatment Method, 2023 to 2033
Table 43: Europe Market Value (US$ Mn) Analysis, by Route of Administration, 2018 to 2022
Table 44: Europe Market Value (US$ Mn) Analysis, by Route of Administration, 2023 to 2033
Table 45: Europe Market Value (US$ Mn) Opportunity Analysis, by Route of Administration, 2023 to 2033
Table 46: Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2018 to 2022
Table 47: Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2023 to 2033
Table 48: Europe Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2023 to 2033
Table 49: East Asia Market Value (US$ Mn) Analysis, by Country, 2018 to 2022
Table 50: East Asia Market Value (US$ Mn) Analysis, by Country, 2023 to 2033
Table 51: East Asia Market Value (US$ Mn) Opportunity Analysis, by Country, 2023 to 2033
Table 52: East Asia Market Value (US$ Mn) Analysis, by Treatment Method, 2018 to 2022
Table 53: East Asia Market Value (US$ Mn) Analysis, by Treatment Method, 2023 to 2033
Table 54: East Asia Market Value (US$ Mn) Opportunity Analysis, by Treatment Method, 2023 to 2033
Table 55: East Asia Market Value (US$ Mn) Analysis, by Route of Administration, 2018 to 2022
Table 56: East Asia Market Value (US$ Mn) Analysis, by Route of Administration, 2023 to 2033
Table 57: East Asia Market Value (US$ Mn) Opportunity Analysis, by Route of Administration, 2023 to 2033
Table 58: East Asia Market Value (US$ Mn) Analysis, by Distribution Channel, 2018 to 2022
Table 59: East Asia Market Value (US$ Mn) Analysis, by Distribution Channel, 2023 to 2033
Table 60: East Asia Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2023 to 2033
Table 61: South Asia & Oceania Market Value (US$ Mn) Analysis, by Country, 2018 to 2022
Table 62: South Asia & Oceania Market Value (US$ Mn) Analysis, by Country, 2023 to 2033
Table 63: South Asia & Oceania Market Value (US$ Mn) Opportunity Analysis, by Country, 2023 to 2033
Table 64: South Asia & Oceania Market Value (US$ Mn) Analysis, by Treatment Method, 2018 to 2022
Table 65: South Asia & Oceania Market Value (US$ Mn) Analysis, by Treatment Method, 2023 to 2033
Table 66: South Asia & Oceania Market Value (US$ Mn) Opportunity Analysis, by Treatment Method, 2023 to 2033
Table 67: South Asia & Oceania Market Value (US$ Mn) Analysis, by Route of Administration, 2018 to 2022
Table 68: South Asia & Oceania Market Value (US$ Mn) Analysis, by Route of Administration, 2023 to 2033
Table 69: South Asia & Oceania Market Value (US$ Mn) Opportunity Analysis, by Route of Administration, 2023 to 2033
Table 70: South Asia & Oceania Market Value (US$ Mn) Analysis, by Distribution Channel, 2018 to 2022
Table 71: South Asia & Oceania Market Value (US$ Mn) Analysis, by Distribution Channel, 2023 to 2033
Table 72: South Asia & Oceania Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2023 to 2033
Table 73: MEA Market Value (US$ Mn) Analysis, by Country, 2018 to 2022
Table 74: MEA Market Value (US$ Mn) Analysis, by Country, 2023 to 2033
Table 75: MEA Market Value (US$ Mn) Opportunity Analysis, by Country, 2023 to 2033
Table 76: MEA Market Value (US$ Mn) Analysis, by Treatment Method, 2018 to 2022
Table 77: MEA Market Value (US$ Mn) Analysis, by Treatment Method, 2023 to 2033
Table 78: MEA Market Value (US$ Mn) Opportunity Analysis, by Treatment Method, 2023 to 2033
Table 79: MEA Market Value (US$ Mn) Analysis, by Route of Administration, 2018 to 2022
Table 80: MEA Market Value (US$ Mn) Analysis, by Route of Administration, 2023 to 2033
Table 81: MEA Market Value (US$ Mn) Opportunity Analysis, by Route of Administration, 2023 to 2033
Table 82: MEA Market Value (US$ Mn) Analysis, by Distribution Channel, 2018 to 2022
Table 83: MEA Market Value (US$ Mn) Analysis, by Distribution Channel, 2023 to 2033
Table 84: MEA Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2023 to 2033
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Value (US$ Mn) Historical Analysis, 2018 to 2022
Figure 02: Global Market Value (US$ Mn) Forecast and Analysis, 2023 to 2033
Figure 03: Global Market Value Y-o-Y Growth and Forecast, 2018 to 2033
Figure 04: Global Market Incremental $ Opportunity, 2023 to 2033
Figure 05: Global Market Share and BPS Analysis by Treatment Method, 2023 & 2033
Figure 06: Global Market Y-o-Y Growth Projections by Treatment Method, 2023 to 2033
Figure 07: Global Market Attractiveness Analysis by Treatment Method, 2023 to 2033
Figure 08: Global Market Share and BPS Analysis by Route of Administration, 2023 & 2033
Figure 09: Global Market Y-o-Y Growth Projections by Route of Administration, 2023 to 2033
Figure 10: Global Market Attractiveness Analysis by Route of Administration, 2023 to 2033
Figure 11: Global Market Share and BPS Analysis by Distribution Channel, 2023 & 2033
Figure 12: Global Market Y-o-Y Growth Projections by Distribution Channel, 2023 to 2033
Figure 13: Global Market Attractiveness Analysis by Distribution Channel, 2023 to 2033
Figure 14: Global Market Share and BPS Analysis by Region, 2023 & 2033
Figure 15: Global Market Y-o-Y Growth Projections by Region, 2023 to 2033
Figure 16: Global Market Attractiveness Analysis by Region, 2023 to 2033
Figure 17: North America Market Value (US$ Mn) Historical Analysis, 2018 to 2022
Figure 18: North America Market Value (US$ Mn) Forecast and Analysis, 2023 to 2033
Figure 19: North America Market Value Y-o-Y Growth and Forecast, 2033
Figure 20: North America Market Incremental $ Opportunity, 2023 to 2033
Figure 21: North America Market Share Analysis by Country, 2023 & 2033
Figure 22: North America Market Y-o-Y Growth Projection by Country, 2023 to 2033
Figure 23: North America Market Attractiveness Analysis by Country, 2023 to 2033
Figure 24: North America Market Share and BPS Analysis by Treatment Method, 2023 & 2033
Figure 25: North America Market Y-o-Y Growth Projections by Treatment Method, 2023 to 2033
Figure 26: North America Market Attractiveness Analysis by Treatment Method, 2023 to 2033
Figure 27: North America Market Share and BPS Analysis by Route of Administration, 2023 & 2033
Figure 28: North America Market Y-o-Y Growth Projections by Route of Administration, 2023 to 2033
Figure 29: North America Market Attractiveness Analysis by Route of Administration, 2023 to 2033
Figure 30: North America Market Share and BPS Analysis by Distribution Channel, 2023 & 2033
Figure 31: North America Market Y-o-Y Growth Projections by Distribution Channel, 2023 to 2033
Figure 32: North America Market Attractiveness Analysis by Distribution Channel, 2023 to 2033
Figure 33: Latin America Market Value (US$ Mn) Historical Analysis, 2018 to 2022
Figure 34: Latin America Market Value (US$ Mn) Forecast and Analysis, 2023 to 2033
Figure 35: Latin America Market Value Y-o-Y Growth and Forecast, 2018 to 2033
Figure 36: Latin America Market Incremental $ Opportunity, 2023 to 2033
Figure 37: Latin America Market Share Analysis by Country, 2023 & 2033
Figure 38: Latin America Market Y-o-Y Growth Projection by Country, 2023 to 2033
Figure 39: Latin America Market Attractiveness Analysis by Country, 2023 to 2033
Figure 40: Latin America Market Share and BPS Analysis by Treatment Method, 2023 & 2033
Figure 41: Latin America Market Y-o-Y Growth Projections by Treatment Method, 2023 to 2033
Figure 42: Latin America Market Attractiveness Analysis by Treatment Method, 2023 to 2033
Figure 43: Latin America Market Share and BPS Analysis by Route of Administration, 2023 & 2033
Figure 44: Latin America Market Y-o-Y Growth Projections by Route of Administration, 2023 to 2033
Figure 45: Latin America Market Attractiveness Analysis by Route of Administration, 2023 to 2033
Figure 46: Latin America Market Share and BPS Analysis by Distribution Channel, 2023 & 2033
Figure 47: Latin America Market Y-o-Y Growth Projections by Distribution Channel, 2023 to 2033
Figure 48: Latin America Market Attractiveness Analysis by Distribution Channel, 2023 to 2033
Figure 49: Europe Market Value (US$ Mn) Historical Analysis, 2018 to 2022
Figure 50: Europe Market Value (US$ Mn) Forecast and Analysis, 2023 to 2033
Figure 51: Europe Market Value Y-o-Y Growth and Forecast, 2018 to 2033
Figure 52: Europe Market Incremental $ Opportunity, 2023 to 2033
Figure 53: Europe Market Share Analysis by Country, 2023 & 2033
Figure 54: Europe Market Y-o-Y Growth Projection by Country, 2023 to 2033
Figure 55: Europe Market Attractiveness Analysis by Country, 2023 to 2033
Figure 56: Europe Market Share and BPS Analysis by Treatment Method, 2023 & 2033
Figure 57: Europe Market Y-o-Y Growth Projections by Treatment Method, 2023 to 2033
Figure 58: Europe Market Attractiveness Analysis by Treatment Method, 2023 to 2033
Figure 59: Europe Market Share and BPS Analysis by Route of Administration, 2023 & 2033
Figure 60: Europe Market Y-o-Y Growth Projections by Route of Administration, 2023 to 2033
Figure 61: Europe Market Attractiveness Analysis by Route of Administration, 2023 to 2033
Figure 62: Europe Market Share and BPS Analysis by Distribution Channel, 2023 & 2033
Figure 63: Europe Market Y-o-Y Growth Projections by Distribution Channel, 2023 to 2033
Figure 64: Europe Market Attractiveness Analysis by Distribution Channel, 2023 to 2033
Figure 65: East Asia Market Value (US$ Mn) Historical Analysis, 2018 to 2022
Figure 66: East Asia Market Value (US$ Mn) Forecast and Analysis, 2023 to 2033
Figure 67: East Asia Market Value Y-o-Y Growth and Forecast, 2018 to 2033
Figure 68: East Asia Market Incremental $ Opportunity, 2023 to 2033
Figure 69: East Asia Market Share Analysis by Country, 2023 & 2033
Figure 70: East Asia Market Y-o-Y Growth Projection by Country, 2023 to 2033
Figure 71: East Asia Market Attractiveness Analysis by Country, 2023 to 2033
Figure 72: East Asia Market Share and BPS Analysis by Treatment Method, 2023 & 2033
Figure 73: East Asia Market Y-o-Y Growth Projections by Treatment Method, 2023 to 2033
Figure 74: East Asia Market Attractiveness Analysis by Treatment Method, 2023 to 2033
Figure 75: East Asia Market Share and BPS Analysis by Route of Administration, 2023 & 2033
Figure 76: East Asia Market Y-o-Y Growth Projections by Route of Administration, 2023 to 2033
Figure 77: East Asia Market Attractiveness Analysis by Route of Administration, 2023 to 2033
Figure 78: East Asia Market Share and BPS Analysis by Distribution Channel, 2023 & 2033
Figure 79: East Asia Market Y-o-Y Growth Projections by Distribution Channel, 2023 to 2033
Figure 80: East Asia Market Attractiveness Analysis by Distribution Channel, 2023 to 2033
Figure 81: South Asia & Oceania Market Value (US$ Mn) Historical Analysis, 2018 to 2022
Figure 82: South Asia & Oceania Market Value (US$ Mn) Forecast and Analysis, 2023 to 2033
Figure 83: South Asia & Oceania Market Value Y-o-Y Growth and Forecast, 2018 to 2033
Figure 84: South Asia & Oceania Market Incremental $ Opportunity, 2023 to 2033
Figure 85: South Asia & Oceania Market Share Analysis by Country, 2023 & 2033
Figure 86: South Asia & Oceania Market Y-o-Y Growth Projection by Country, 2023 to 2033
Figure 87: South Asia & Oceania Market Attractiveness Analysis by Country, 2023 to 2033
Figure 88: South Asia & Oceania Market Share and BPS Analysis by Treatment Method, 2023 & 2033
Figure 89: South Asia & Oceania Market Y-o-Y Growth Projections by Treatment Method, 2023 to 2033
Figure 90: South Asia & Oceania Market Attractiveness Analysis by Treatment Method, 2023 to 2033
Figure 91: South Asia & Oceania Market Share and BPS Analysis by Route of Administration, 2023 & 2033
Figure 92: South Asia & Oceania Market Y-o-Y Growth Projections by Route of Administration, 2023 to 2033
Figure 93: South Asia & Oceania Market Attractiveness Analysis by Route of Administration, 2023 to 2033
Figure 94: South Asia & Oceania Market Share and BPS Analysis by Distribution Channel, 2023 & 2033
Figure 95: South Asia & Oceania Market Y-o-Y Growth Projections by Distribution Channel, 2023 to 2033
Figure 96: South Asia & Oceania Market Attractiveness Analysis by Distribution Channel, 2023 to 2033
Figure 97: MEA Market Value (US$ Mn) Historical Analysis, 2018 to 2022
Figure 98: MEA Market Value (US$ Mn) Forecast and Analysis, 2023 to 2033
Figure 99: MEA Market Value Y-o-Y Growth and Forecast, 2018 to 2033
Figure 100: MEA Market Incremental $ Opportunity, 2023 to 2033
Figure 101: MEA Market Share Analysis by Country, 2023 & 2033
Figure 102: MEA Market Y-o-Y Growth Projection by Country, 2023 to 2033
Figure 103: MEA Market Attractiveness Analysis by Country, 2023 to 2033
Figure 104: MEA Market Share and BPS Analysis by Treatment Method, 2023 & 2033
Figure 105: MEA Market Y-o-Y Growth Projections by Treatment Method, 2023 to 2033
Figure 106: MEA Market Attractiveness Analysis by Treatment Method, 2023 to 2033
Figure 107: MEA Market Share and BPS Analysis by Route of Administration, 2023 & 2033
Figure 108: MEA Market Y-o-Y Growth Projections by Route of Administration, 2023 to 2033
Figure 109: MEA Market Attractiveness Analysis by Route of Administration, 2023 to 2033
Figure 110: MEA Market Share and BPS Analysis by Distribution Channel, 2023 & 2033
Figure 111: MEA Market Y-o-Y Growth Projections by Distribution Channel, 2023 to 2033
Figure 112: MEA Market Attractiveness Analysis by Distribution Channel, 2023 to 2033
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What is the cystic fibrosis devices market value in 2023?
The global cystic fibrosis devices market is valued at US$ 825.09 million in 2023.
What is the projected market value for 2033?
Revenue from the sales of cystic fibrosis devices is expected to reach US$ 2.14 billion by 2033.
What is the predicted growth rate for the cystic fibrosis devices market?
Global demand for cystic fibrosis devices is predicted to increase at a CAGR of 10% during the forecast period.
Who is a leading manufacturer of cystic fibrosis devices?
Vertex Pharmaceuticals Incorporated holds a significant position in the global market.
Which is a lucrative regional market for cystic fibrosis device producers?
North America is considered a lucrative market due to the high prevalence of CF disorders in the region.
Cystic Fibrosis Devices Market